Serina Therapeutics, Inc. Return Tang Equity
Return on tangible equity is the profit a company earns on the physical and financial capital its shareholders own, leaving out goodwill and other intangible assets, shown as a percentage. It is net income divided by tangible equity, which is shareholder equity minus goodwill and intangibles; the table shows both amounts. Because acquired goodwill is removed, it runs higher than ROE for companies that grew by acquisition, and it has no meaning when goodwill exceeds equity. Goodwill and intangibles are taken at the latest reported date on or before each equity date. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.
- Serina Therapeutics, Inc. return tang equity for the quarter ending 2026-06-30 was -116.21%, a change of 991.18% year-over-year.
- Serina Therapeutics, Inc. return tang equity for the quarter ending 2026-03-31 was -124.23%, a change of -34.80% year-over-year.
- Serina Therapeutics, Inc. return tang equity for the quarter ending 2025-12-31 was 3513.19%, a 99.68% decline year-over-year.
- Serina Therapeutics, Inc. return tang equity for the quarter ending 2025-09-30 was -1713.00%, a 3441.39% decline year-over-year.
- Serina Therapeutics, Inc. return tang equity for fiscal 2025 was 2978.57%, a 73.53% decline from fiscal 2024.
- Serina Therapeutics, Inc. return tang equity for fiscal 2024 was 11253.54%, a change of 11269.55% from fiscal 2023.
- Serina Therapeutics, Inc. return tang equity for fiscal 2023 was -16.01%, a 158.76% decline from fiscal 2022.
- Serina Therapeutics, Inc. return tang equity for fiscal 2022 was 27.26%, a 59.96% decline from fiscal 2021.
- Available history
- 2017-12-31 to 2026-06-30
- Data captured
Historical Return Tang Equity
Annual Return Tang Equity
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B |